NEW YORK - Computational biology researchers today announced a new Internet tool for the exploration of the scientific literature in medicine and biology. The freely accessible iHOP service provides fast, accurate, comprehensive, and up-to-date summary information on more than 80,000 biological molecules by automatically extracting key sentences from millions of PubMed documents when a search is requested.
NEW YORK - Jacqueline Barnes, RN, MPH, of Memorial Sloan-Kettering Cancer Center and a resident of Roosevelt Island, NY, has been recognized for outstanding patient care with a New York Times Job Market "Tribute to Nurses" award.
NEW YORK - Memorial Sloan-Kettering Cancer Center is one of six leading institutions that will share in a $120 million gift from a foundation created by American billionaire Daniel K. Ludwig.
NEW YORK - Almost three-fourths of pediatric cancer survivors will have a chronic health problem within 30 years after the cancer diagnosis, with 40 percent experiencing a serious, life-threatening, disabling, or fatal condition, according to investigators from Memorial Sloan-Kettering Cancer Center (MSKCC), St. Jude Children's Research Hospital, and other institutions.
NEW YORK - A gift from the estate of renowned fashion designer Geoffrey Beene will enable MSKCC to launch an ambitious research initiative to be known as the Geoffrey Beene Cancer Research Center.
NEW YORK - Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years.
NEW YORK - The Starr Foundation today announced that it has made a $100 million grant to create a wide-ranging cancer consortium to coordinate the efforts of five internationally renowned research institutions in the fight against cancer. Joining this ambitious undertaking are The Broad Institute of MIT and Harvard, Cold Spring Harbor Laboratory, Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College.
NEW YORK - Memorial Sloan-Kettering Cancer Center (MSKCC) is now poised to take greater advantage of a new era in cancer research and education with the opening of a state-of-the-art research center, the establishment of a new graduate school, and the founding of a novel research program in human oncology.
BASKING RIDGE, NJ - Memorial Sloan-Kettering Cancer Center (MSKCC) opened a new state-of-the-art outpatient cancer treatment facility in Basking Ridge, New Jersey, today. The new 85,000-square-foot facility incorporates the latest concepts in therapeutic design and offers the most advanced cancer care services.
NEW YORK - A retrospective study by urologists at MSKCC and their colleagues, suggests that this practice needs to be re-evaluated. Researchers add that with advances in imaging, almost 70 percent of kidney cancer patients have their tumor detected at a very small size allowing surgeons to perform less radical surgery with superior results.
NEW YORK - The Tri-Institutional Stem Cell Initiative, comprised of three leading New York City biomedical research institutions -- Memorial Sloan-Kettering Cancer Center, The Rockefeller University, and Weill Medical College of Cornell University -- has announced the first wave of stem cell research projects to be funded through a $50 million gift from The Starr Foundation.
NEW YORK - Memorial Sloan-Kettering Cancer Center (MSKCC) has opened a new 72,000-square-foot surgical center that was uniquely designed to take advantage of the latest medical technology while enhancing patient safety and efficiency of care.
ATLANTA - A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation. The results of the study, which are being presented today at the annual American Society of Clinical Oncology meeting, also provide the strongest evidence to date that this surgery significantly reduces the overall risk of BRCA-associated breast and ovarian cancers.
ATLANTA - According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.
NEW YORK - Memorial Sloan-Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan-Kettering's new cancer research facility, including a 23-story laboratory structure that opens this month. Mr. Zuckerman's donation is the largest single commitment by an individual in Memorial Sloan-Kettering's history.
NEW YORK - The New York Yankees and Memorial Sloan-Kettering Cancer Center have announced a new and unprecedented initiative to raise funds to help support research and treatment for children with cancer.
NEW YORK - Scientists have uncovered new information about what orchestrates the complex balance between blood stem cells and mature blood cells, a relationship that is often disrupted in leukemia. The results will lead to a better understanding of the behavior of leukemic cells and may have vital clinical applications for patients recovering from chemotherapy, radiation therapy, or bone marrow transplantation.
NEW YORK - A multi-institutional study led by Memorial Sloan-Kettering Cancer Center (MSKCC) shows that patients whose colorectal cancer has spread to the liver and who received chemotherapy directly to the liver through a pump in the abdomen (an approach called Hepatic Arterial Infusion or HAI) fare better than those who received systemic (intravenously administered) chemotherapy.
NEW YORK - Women with Stage III ovarian cancer when treated with a combination of intravenous (IV) and intra-abdominal chemotherapy, following the successful surgical removal of tumors, survived almost a year longer than those who received IV chemotherapy alone.
NEW YORK - Researchers led by a team of scientists at Memorial Sloan-Kettering Cancer Center have devised a novel strategy that uses stem cell-based gene therapy and RNA interference to genetically reverse sickle cell disease (SCD) in human cells. This research is the first to demonstrate a way to genetically correct this debilitating blood disease using RNA interference technology.
NEW YORK - Three young investigators who have made major accomplishments in cancer research will be the recipients of the 2005 Paul Marks Prize for Cancer Research and will share a $150,000 award.
NEW YORK - A team of researchers led by scientists at Memorial Sloan-Kettering Cancer Center have discovered that a new class of drugs -- now in early stage clinical trials -- work best in patients with mutations in the BRAF gene.
NEW YORK - Your cancer is under control, but how is everything else? This is not a question cancer patients expect to be asked, but with millions of cancer survivors in the United States living longer, there's a growing need and increased interest in making sure that they are living better.
NEW YORK - Memorial Sloan-Kettering Cancer Center researchers have found that melanoma patients with a family history of melanoma and/or dysplastic nevi (abnormal moles) are at high risk of developing multiple primary melanomas (MPM).
NEW YORK - Women with a strong family history of breast cancer but who don't have breast cancer genetic mutations can now be reassured that they are not at increased risk for ovarian cancer.
NEW YORK - Researchers at Memorial Sloan-Kettering Cancer Center found that prostate tumor growth is arrested through a biological process called cellular senescence, in which cells stop proliferating and remain alive but fail to respond to normal growth signals.
NEW YORK - Scientists at Memorial Sloan-Kettering have identified a set of genes in breast tumors that appear to predict if breact cancer will spread to the lungs and, once there, how virulent it will become.
NEW YORK - According to research published today, investigators from Memorial Sloan-Kettering Cancer Center have used new techniques in the laboratory that allowed them for the first time to derive unlimited numbers of purified mesenchymal precursor cells from human embryonic stem cells (HESCs).
NEW YORK - Scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) have uncovered the structure of a network of proteins that help regulate the life cycle of cells. Understanding the network's physical layout is an important step toward learning its precise function, and in finding ways to correct flaws in the system that could lead to cancer.
NEW YORK - Three New York City biomedical research institutions -- The Rockefeller University, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center (MSKCC) -- will receive $50 million over three years from The Starr Foundation to develop new resources and expertise in stem cell research.
ORLANDO - A prospective, randomized trial comparing a novel regimen with a standard treatment for adult patients with acute lymphocytic leukemia (ALL) showed a distinct advantage that continued to show superior results at three-, four-, and five-year intervals in the investigational arm of the trial.
NEW YORK - Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have found an explanation for why some lung cancers stop responding to the drugs erlotinib (TarcevaTM) and gefitinib (Iressa®). This discovery may lead to the development of new therapies to use when these agents stop working. The research is to be published online in the open-access international journal PLoS Medicine on February 22, 2005.
NEW YORK - Nominations are currently being sought for the Paul Marks Prize for Cancer Research. The prize recognizes outstanding young investigators who have made significant contributions to increase the understanding of cancer or improve the treatment of the disease through basic or clinical research.
NEW YORK - Scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) have identified a new cellular oncogene essential for the development of cancer.
NEW YORK - A new study by researchers at Memorial Sloan-Kettering Cancer Center and The Johns Hopkins University provides new insight into how tumor cells can become resistant to anti-cancer therapy.
NEW YORK - Memorial Sloan-Kettering Cancer Center (MSKCC) today announced the establishment of a new graduate school of biomedical sciences. It will offer a novel doctoral program that will train basic laboratory scientists to work in research areas directly applicable to human disease and, in particular, to cancer.
NEW YORK - A new center for children with cancer has been created at Memorial Sloan-Kettering Cancer Center. The 45,428 square-foot Claire Tow Pediatric Pavilion includes a day hospital and a unit for inpatients. It is designed to create a bright and comforting second home for children and families during cancer treatment, which often lasts 12 to 24 months.
NEW YORK - Researchers at Memorial Sloan-Kettering Cancer Center report that 15 embryonic stem cells injected into early embryos of mice whose hearts were genetically predisposed to develop a lethal defect, rescued the heart from developing the disorder by not only producing normal daughter cells that were incorporated into the defective embryonic heart but also by releasing biological factors into the nearby vicinity. This prevented neighboring heart cells from developing into defective tissue.
ATLANTA - Experts from Memorial Sloan-Kettering Cancer Center (MSKCC) will present the latest advances in the use of radiation therapy to treat various cancers at this year's 46th Annual Meeting of the Society of Therapeutic Radiology and Oncology (ASTRO) in Atlanta, GA.
BASKING RIDGE, NJ - Memorial Sloan-Kettering Cancer Center (MSKCC) today announced construction of a new outpatient cancer treatment facility in New Jersey. The new facility will incorporate the latest concepts in therapeutic design and offer the latest advances in cancer care.
NEW YORK - Mesothelioma is an aggressive cancer of the chest cavity that kills about 2000 people a year in the United States. Seventy to eighty percent of patients with this rare cancer have had exposure to asbestos. It has also been proposed that simian virus 40 (SV40), a contaminant in some polio vaccines administered in the 1950's and 1960's, might be a cause. However, studies reporting the detection of SV40 DNA in human tumors (including mesotheliomas, and also some lymphomas, brain cancers, and bone cancers) have not consistently yielded the same results when repeated by other groups. This has fueled an ongoing debate over laboratory methods and the strength of the association of SV40 with these tumors.
NEW YORK - Many cancers, including colon, prostate, and leukemia, continue to grow unchecked because they do not respond to a signal to die and stop proliferating from Transforming Growth Factor-beta (TGF-b). For the first time, scientists at Memorial Sloan-Kettering Cancer Center have discovered the biologic function of the cytoplasmic form of the Promyelocytic Leukemia protein (PML), and identified it as an essential factor in maintaining TGF-b signaling.
NEW YORK - If you are a black Medicare patient in the United States, you are more likely than a white Medicare patient to be treated by a primary care physician who reports being unable to provide consistently high-quality medical care to all patients.
NEW YORK - James Allison, PhD, has been named the new Chairman of the Immunology Program at Memorial Sloan-Kettering Cancer Center (MSKCC). He succeeds Alan Houghton, MD, who has led the Program since 1995.
DETROIT - Dr. Thomas Kelly, Director, Sloan-Kettering Institute, has been awarded the Alfred P. Sloan, Jr. Prize, one of three awards given annually by the General Motors Cancer Research Foundation (GMCRF).
NEW ORLEANS - Recent findings in a national study demonstrated that women with advanced breast cancer have improved response rates and prolonged time to disease progression when they received weekly paclitaxel (Taxol™) versus the standard every 3-week therapy.
NEW ORLEANS - A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy-resistant of all cancers. The study's lead investigator, Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported the results of a Phase II study today at the American Society for Clinical Oncology annual meeting.
NEW YORK - Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs at Memorial Sloan-Kettering Cancer Center, is the recipient of the 2004 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology (ASCO).
NEW YORK - A new study shows that the risk for prostate cancer is significantly elevated in men who are part of families with a hereditary form of breast and ovarian cancer.
NEW YORK - A new anti-cancer agent, gefitinib (Iressa), recently received FDA approval for patients with advanced non-small cell lung cancer (NSCLC) after a series of clinical trials and an expanded access program led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).
NEW YORK - Memorial Sloan-Kettering Cancer Center (MSKCC) is pleased to announce the appointment of David Spriggs, MD, as Head of the Division of Solid Tumor Oncology in the Department of Medicine.
NEW YORK - An abnormal or rising prostate specific antigen (PSA) blood test is often the first indication that a man may have prostate cancer. Even after diagnosis, the test continues to play a role in monitoring disease progression and assessing treatment outcomes. However, after a man has received curative therapy, there is uncertainty about what the PSA measurement means since the relationship of tumor mass and PSA value is less established at this time.
NEW YORK - Royalty Pharma acquired a portion of Memorial Sloan-Kettering Cancer Center's ("MSKCC") U.S. royalty interest in Neupogen/Neulasta, the entities announced today. Under the agreement, MSKCC received $263 million in cash up-front plus certain additional payments should Neupogen/Neulasta yearly sales exceed certain agreed sales hurdles. In addition, as part of the agreement, MSKCC has made a $7 million investment in Royalty Pharma.
